April 7, 2017 / 9:43 PM / in 2 years

Novartis sues Mylan over generic version of cancer drug Afinitor

Novartis AG on Friday filed a patent infringement lawsuit seeking to block Mylan Inc from launching a generic version of cancer drug Afinitor.

Basel, Switzerland-based Novartis sued Mylan in federal court in Delaware, alleging the latter company’s proposed generic would infringe on three patents related to Afinitor. Mylan is also seeking a declaration that its patents are invalid.

To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2nTSBTQ

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below